ROSWELL, Ga., Jan. 14, 2019 /PRNewswire-PRWeb/ -- The Centers for Disease Control (CDC) has updated information related to the use and availability of VARIZIG® (Varicella Zoster Immune Globulin [Human ...

Please provide your email address to receive an email when new articles are posted on . Over the past several months, two new agents have become available to aid clinicians in preventing infections ...

Dublin, April 14, 2026 (GLOBE NEWSWIRE)-- The "VariZIG Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ...

REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ...

(RTTNews) - Kamada Ltd. (KMDA), a biopharmaceutical company specializing in rare and serious conditions, announced on Monday that it has been awarded a three-year contract with an international ...

Varicella zoster immune globulin (VZIG) has been the mainstay of therapy for postexposure prophylaxis of varicella for patients at high risk for severe disease and complications. However, the U.S.